NCT01997840View on ClinicalTrials.gov

ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

103

Participants

Timeline

Start Date

March 1, 2014

Primary Completion Date

February 29, 2024

Study Completion Date

February 29, 2024

Conditions
Multiple Myeloma
Interventions
DRUG

ACY-1215 (Ricolinostat) in combination with pomalidomide and dexamethasone

ACY-1215 (Ricolinostat) 160mg QD Days 1-21 with pomalidomide 4mg QD Days 1-21 and dexamethasone 40mg QD Days 1,8,15,22 of a 28-day cycle

Trial Locations (2)

44195

Cleveland Clinic, Cleveland

02215

Local Institution - 201, Boston

Sponsors

Lead Sponsor

Celgene
All Listed Sponsors
lead

Celgene

INDUSTRY

NCT01997840 - ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter